1. Introduction {#sec1}
===============

Spasticity has been described as disordered sensorimotor control, resulting from an upper motor neuron lesion, presenting as intermittent or sustained involuntary activation of muscles ([@bib35], [@bib43]). Spasticity affects coordinated movement of the shoulder, elbow, wrist, and finger flexors in the upper limb, and the ankle, knee, and hip in the lower limb, resulting in abnormal postures and limb pain ([@bib1], [@bib31], [@bib44]). Upper and/or lower limb spasticity can negatively impact a patient\'s ability to perform daily activities, leading to reduced health-related quality of life and significant socioeconomic impacts ([@bib6], [@bib24], [@bib29]).

Spasticity is a disabling consequence of many central nervous system disorders, including stroke, multiple sclerosis (MS), cerebral palsy (CP), traumatic brain injury (TBI), spinal cord injury (SCI), and intracerebral hemorrhage (ICH). Approximately 17--43% of post-stroke patients experience spasticity ([@bib50]), while 34--84% of patients with moderate to severe TBI ([@bib5], [@bib47]), 31--78% of patients with SCI ([@bib5], [@bib19], [@bib23]), 40--80% of patients with MS ([@bib7], [@bib14], [@bib39]), and across their lifetime, 72--91% of patients with CP ([@bib34]) are affected by spasticity. Many factors can influence the reported incidence of spasticity, including those that impact detection and/or influence appearance/severity. These include time from the event/diagnosis, the method(s) of diagnosis or the assessment scale(s) utilized, as well as various triggers that are extrinsic (eg, time of day, temperature, or fit of devices; [@bib12], [@bib24], [@bib33]) or intrinsic/patient-specific comorbid conditions (eg, bladder or bowel issues, menstrual cycle, skin, and fever; [@bib12], [@bib33]).

Clinical treatment strategies to manage spasticity (see reviews: [@bib27], [@bib46]) often include several modalities ([@bib32], [@bib49]) to address the specific needs and goals of the individual patient. Individual treatment focuses on addressing symptoms, preventing further complications, restoring function, and improving quality of life ([@bib16], [@bib33]). OnabotulinumtoxinA (BOTOX®, Allergan, an AbbVie company, North Chicago, Illinois, USA) is approved for use in the management of upper and lower limb spasticity in the U.S.A. and worldwide ([@bib2]) and is often used in combination with other supporting treatments, such as physical and occupational therapy. The use of onabotulinumtoxinA in controlled trials to treat post-stroke spasticity is well-established (eg, [@bib8], [@bib25], [@bib26], [@bib36]). However, there are limited data describing the use of onabotulinumtoxinA in real-world clinical practice to treat spasticity across a range of etiologies ([@bib18]). Real-world, observational data are necessary to improve educational programs on spasticity management and help guide clinical strategies to optimize patient care. The [A]{.ul}dult [SP]{.ul}asticity [I]{.ul}nternational [RE]{.ul}gistry (ASPIRE) study was developed to describe the clinical characteristics of adult patients being treated with onabotulinumtoxinA for spasticity in the real-world and its burden across several etiologies and geographical regions ([@bib20]). The goals of this 1-year interim analysis of ASPIRE were to describe the patterns of onabotulinumtoxinA utilization across several etiologies of spasticity and evaluate the effectiveness of onabotulinumtoxinA to treat spasticity across these etiologies via clinician- and patient-reported outcomes.

2. Methods {#sec2}
==========

The ASPIRE study methods have been published previously ([@bib20]) and are described in brief below.

2.1. Study design and setting {#sec2.1}
-----------------------------

ASPIRE is an international, multicenter, prospective, observational registry (NCT01930786). Data were collected by 74 treating clinicians across 54 international sites in North America, Europe, and Asia. OnabotulinumtoxinA treatments were administered at the clinician\'s discretion with no intervention from the sponsor in accordance with usual clinical practices and country-specific regulations. The design of ASPIRE included a 96-week study period, followed by a 12-week follow-up period for the collection of any additional safety data, for 108 weeks total. For this 1-year interim analysis, data from the first year of treatment, defined as 365 days after the first administration of onabotulinumtoxinA, were analyzed for each patient. For most patients, re-treatment is expected to occur approximately every 12 weeks according to the SmPC and package insert ([@bib2], [@bib3]). However, the frequency of onabotulinumtoxinA treatments in real-world clinical practice varies according to many factors, including severity of spasticity, patient goals, the clinician\'s approach, administrative/logistical constraints, and others. Financial support was not provided by the sponsor for any treatment/treatment related costs. ASPIRE was conducted in accordance with all relevant regulatory requirements, including the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices (International Society for Pharmacoepidemiology \[IPSE\]).

2.2. Participants {#sec2.2}
-----------------

Adult patients (≥18 years of age) that were either naïve or non-naïve to botulinum toxin(s) for spasticity were included in ASPIRE. Please refer to [@bib20] for details on ASPIRE inclusion/exclusion criteria. Patients were treated with onabotulinumtoxinA for focal spasticity related to upper motor neuron syndrome during routine clinical practice. All patients were required to provide written informed consent. IRB/IEC approval was granted at each study site.

2.3. Outcomes and data sources {#sec2.3}
------------------------------

Patient demographics and clinical characteristic data, including etiology of spasticity, were collected at baseline. Etiology was not mutually exclusive, as more than one response was allowed per patient. Data from patients who reported more than one etiology were included for each identified etiology (eg, stroke and MS). The etiology(ies) identified at baseline were maintained across all treatment sessions for this analysis, regardless of changes in health status during the study. To investigate the impact of etiology of spasticity on onabotulinumtoxinA treatment patterns, utilization data were captured at each treatment session. To better understand the impact of onabotulinumtoxinA on patient-reported outcomes (PROs), changes in functional impairment were determined using the Disability Assessment Scale (DAS; [@bib9]) and clinician- and patient-reported satisfaction data were gathered throughout the study. DAS was assessed by the clinician at treatment session 1 and at each subsequent treatment session. Clinician satisfaction was collected at each subsequent treatment session and patient satisfaction was collected 5±1 weeks post-treatment. Adverse event (AE) data were captured throughout the 1-year period and were summarized using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.0 by system organ class and preferred term. Relationship to treatment and evaluation of potential distant spread of toxin were adjudicated by a panel of safety clinicians. For additional details on the assessment scales utilized in ASPIRE, as well as a complete list of data collected, refer to [@bib20].

2.4. Statistical methods {#sec2.4}
------------------------

No formal sample size/statistical power calculations were performed as analyses of the primary study objectives were descriptive and did not test specific hypotheses. Observed data are shown; no imputation of missing values was performed. Statistical significance was determined using ordinal logistic regression for DAS. Descriptive statistics were performed using SAS version 9.2 or higher (SAS Institute, Cary, NC, USA).

3. Results {#sec3}
==========

3.1. Patient disposition, demographics, and clinical characteristics {#sec3.1}
--------------------------------------------------------------------

At the 1-year interim, 730 patients received at least one treatment of onabotulinumtoxinA to the upper and/or lower limb during at least one treatment session. The most common etiologies of spasticity at baseline were stroke (N=411/730 56.3% of patients), MS (N=119/730, 16.3%), CP (N=77/730, 10.5%), TBI (N=45/730, 6.2%), and SCI (N=42/730, 5.8%; [Fig. 1](#fig1){ref-type="fig"}). In total, 35 patients reported multiple etiologies at baseline: 34 patients reported 2 etiologies and 1 patient reported 3 etiologies. Etiologies in addition to those listed above were included in a category labeled "other". Due to the diversity of underlying etiologies captured in other, meaningful conclusions about this category could not be drawn, and therefore, results are not presented in this manuscript. Approximately 1/3 of the total patient population was naïve to botulinum toxins for spasticity ([Fig. 1](#fig1){ref-type="fig"}). The proportion of patients naïve to botulinum toxin(s) was slightly higher in stroke, TBI, and SCI.Fig. 1Etiology of spasticity at baseline. Within each etiology, the sum of naïve and non-naïve patients is 100%. Etiologies were not mutually exclusive, as more than one response was allowed per patient. ^†^Stroke includes ischemic, hemorrhagic, and embolic stroke. ^‡^Other includes hereditary spastic paraparesis, stroke during aneurysm clipping, Chairi malformation, and hydrocephalus. N: number of patients.Fig. 1

Baseline patient demographics and clinical characteristics for each etiology are shown in [Table 1](#tbl1){ref-type="table"}. The mean age of patients ranged from 37.6 years old (CP) to 58.7 years old (stroke). Gender was evenly distributed in the stroke population, but was skewed towards more females in MS and CP, and more males in TBI and SCI, concordant with real-world prevalence and incidence. Race and BMI were similar across etiologies. The pattern of spasticity at baseline varied by etiology, with upper limb spasticity highest in stroke patients (N=377/411, 91.7%) and lowest in MS patients (N=40/119, 33.6%). Conversely, lower limb spasticity was highest in MS patients (N=114/119, 95.8%) and lowest in stroke patients (N=327/411, 79.6%). For each etiology, the percentage (number) of patients that withdrew consent and discontinued the study ≤365 days after their first treatment were as follows: 22.4% (N=92) of patients in stroke, 16.8% (N=20) in MS, 13% (N=10) in CP, 17.8% (N=8) in TBI, and 23.8% (N=10) in SCI.Table 1Baseline patient demographics and clinical characteristics.Table 1Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)Age (years) Mean (SD)58.7 (14.1)53.1 (10.3)37.6 (13.4)42.8 (12.9)50.9 (16.0) Median59.453.134.440.451.3 Min, Max19.2, 93.224.7, 77.718.5, 68.120.2, 73.522.8, 93.2Gender, N (%) Female203 (49.4)83 (69.7)45 (58.4)16 (35.6)17 (40.5) Male208 (50.6)36 (30.3)32 (41.6)29 (64.4)25 (59.5)Race, N (%) Caucasian309 (75.2)99 (83.2)65 (84.4)32 (71.1)26 (61.9) Black/African/Caribbean54 (13.1)9 ( 7.6)9 (11.7)5 (11.1)8 (19.0) Asian32 ( 7.8)0 ( 0.0)1 ( 1.3)6 (13.3)5 (11.9) Latino/Hispanic10 ( 2.4)1 ( 0.8)2 ( 2.6)1 ( 2.2)2 ( 4.8) Other6 ( 1.4)10 ( 8.4)0 ( 0.0)1 ( 2.2)1 ( 2.4)BMI (kg/m^2^), N35196613836 Mean (SD)27.2 (5.2)25.6 (5.4)27.4 (8.1)24.6 (4.8)26.0 (5.1) Median26.224.725.623.125.3 Min, Max17.3, 44.514.9, 42.215.5, 56.818.0, 37.117.2, 41.5Pattern of spasticity, N (%) Upper limb spasticity377 (91.7)40 (33.6)47 (61.0)35 (77.8)26 (61.9) Lower limb spasticity327 (79.6)114 (95.8)69 (89.6)39 (86.7)35 (83.3)[^1]

3.2. OnabotulinumtoxinA treatment utilization {#sec3.2}
---------------------------------------------

The upper limb clinical presentations treated in ASPIRE included adducted/internally rotated shoulder, clenched fist, flexed elbow, flexed wrist, intrinsic plus hand, pronated forearm, and thumb-in-palm (refer to [@bib30], [@bib41] for presentation descriptions). The lower limb clinical presentations treated in ASPIRE included adducted thigh, equinovarus foot, flexed hip, flexed knee, flexed toes, stiff extended knee, and striatal/hyperextended/hitchhiker toe (refer to [@bib17], [@bib30] for presentation descriptions). In the upper limb, clenched fist was treated most often in stroke, MS, and SCI, whereas flexed wrist and flexed elbow were most often treated in CP and TBI, respectively. ([Fig. 2](#fig2){ref-type="fig"}A). In the lower limb, equinovarus foot was treated most often in all etiologies ([Fig. 2](#fig2){ref-type="fig"}B).Fig. 2Rank order of upper and lower limb clinical spasticity presentations. Within each etiology, clinical presentations (upper limb: A; lower limb: B) are listed in order of percentage of patients treated across all treatment sessions in the 1-year interim dataset: highest to lowest. Spasticity presentations are not mutually exclusive, and therefore, may add up to greater than100%. Data for "other" clinical presentations not predefined within the case report form, including for non-spasticity indications, are not shown. CP: cerebral palsy, MS: multiple sclerosis, n: number of treatment sessions per clinical presentation, N: number of patients, TBI: traumatic brain injury, SCI: spinal cord injury.Fig. 2

To compare onabotulinumtoxinA utilization across etiologies, the three most common upper limb presentations (ie, clenched fist, flexed elbow, and flexed wrist) and the three most common lower limb presentations (ie, equinovarus foot, flexed knee, adducted thigh) were identified based on percentage of patients treated for each presentation. Detailed utilization data, including number of patients treated, number of treatment sessions, dose, and injection localization methods are provided in [Table 2](#tbl2){ref-type="table"} and [Table 3](#tbl3){ref-type="table"}, demonstrating the real-world diversity of onabotulinumtoxinA treatment, with findings of interest highlighted below. The additional presentations for the upper limb ([Supplemental Table 1](#appsec2){ref-type="fn"}) and the lower limb ([Supplemental Table 2](#appsec2){ref-type="fn"}) are provided in the supplementary materials.Table 2OnabotulinumtoxinA treatment utilization for the most common upper limb clinical presentations.[a](#tbl2fna){ref-type="table-fn"}Table 2Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)CLENCHED FISTPatients, N (%)290 (70.6)15 (12.6)23 (29.9)25 (55.6)17 (40.5)Treatment sessions, n78343666348Dose (U) Mean (SD)100 (60)105 (76)98 (96)127 (64)115 (61) Mode10050100100100 Min, Max10, 50010, 35010, 47520, 30025, 350Localization method, n (%)[b](#tbl2fnb){ref-type="table-fn"} Anatomical277 (35.4)32 (74.4)18 (27.3)11 (17.5)16 (33.3) E-stim153 (19.5)14 (32.6)6 ( 9.1)17 (27.0)13 (27.1) EMG430 (54.9)21 (48.8)41 (62.1)29 (46.0)23 (47.9) Ultrasound208 (26.6)8 (18.6)9 (13.6)25 (39.7)19 (39.6)FLEXED ELBOWPatients, N (%)277 (67.4)15 (12.6)29 (37.7)26 (57.8)12 (28.6)Treatment sessions, n71642826319Dose (U) Mean (SD)116 (75)163 (118)101 (56)126 (46)151 (96) Mode100100100100100 Min, Max15, 60025, 50020, 30020, 22530, 350Localization method, n (%)[b](#tbl2fnb){ref-type="table-fn"} Anatomical221 (30.9)26 (61.9)20 (24.4)10 (15.9)2 (10.5) E-stim102 (14.2)1 ( 2.4)11 (13.4)17 (27.0)1 ( 5.3) EMG403 (56.3)9 (21.4)52 (63.4)33 (52.4)10 (52.6) Ultrasound168 (23.5)11 (26.2)7 ( 8.5)18 (28.6)8 (42.1)FLEXED WRISTPatients, N (%)221 (53.8)8 (6.7)29 (37.7)13 (28.9)8 (19.0)Treatment sessions, n55118923316Dose (U) Mean (SD)79 (58)54 (22)80 (51)95 (41)97 (65) Mode1006050100100 Min, Max10, 50020, 10012, 30025, 20025, 250Localization method, n (%)[b](#tbl2fnb){ref-type="table-fn"} Anatomical156 (28.3)16 (88.9)23 (25.0)3 ( 9.1)9 (56.3) E-stim87 (15.8)1 ( 5.6)16 (17.4)12 (36.4)2 (12.5) EMG328 (59.5)3 (16.7)46 (50.0)21 (63.6)9 (56.3) Ultrasound152 (27.6)2 (11.1)16 (17.4)8 (24.2)3 (18.8)[^2][^3][^4]Table 3OnabotulinumtoxinA treatment utilization for the most common lower limb clinical presentations.[a](#tbl3fna){ref-type="table-fn"}Table 3Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)EQUINOVARUS FOOTPatients, N (%)217 (52.8)72 (60.5)38 (49.4)28 (62.2)20 (47.6)Treatment sessions, n5772091006551Dose (U) Mean (SD)223 (131)206 (124)162 (116)223 (109)277 (168) Mode300300100150200 Min, Max15, 63020, 87520, 48050, 45060, 900Localization method, n (%)[b](#tbl3fnb){ref-type="table-fn"} Anatomical175 (30.3)113 (54.1)22 (22.0)11 (16.9)22 (43.1) E-stim180 (31.2)60 (28.7)22 (22.0)42 (64.6)13 (25.5) EMG288 (49.9)113 (54.1)52 (52.0)21 (32.3)16 (31.4) Ultrasound155 (26.9)37 (17.7)17 (17.0)10 (15.4)13 (25.5)FLEXED KNEEPatients, N (%)39 (9.5)32 (26.9)26 (33.8)12 (26.7)9 (21.4)Treatment sessions, n8099661724Dose (U) Mean (SD)143 (86)181 (122)150 (89)154 (60)165 (84) Mode100150100150200 Min, Max15, 50020, 55030, 32575, 30050, 300Localization method, n (%)[b](#tbl3fnb){ref-type="table-fn"} Anatomical46 (57.5)67 (67.7)19 (28.8)1 ( 5.9)10 (41.7) E-stim10 (12.5)2 ( 2.0)0 ( 0.0)5 (29.4)1 ( 4.2) EMG49 (61.3)45 (45.5)49 (74.2)9 (52.9)15 (62.5) Ultrasound4 ( 5.0)6 ( 6.1)5 ( 7.6)3 (17.6)4 (16.7)ADDUCTED THIGHPatients, N (%)20 (4.9)38 (9.2)17 (22.1)7 (15.6)9 (21.4)Treatment sessions, n43107431522Dose (U) Mean (SD)112 (54)173 (112)163 (94)166 (114)140 (66) Mode100200100150100 Min, Max20, 24025, 50040, 55035, 40050, 300Localization method, n (%)[b](#tbl3fnb){ref-type="table-fn"} Anatomical17 (39.5)77 (72.0)19 (44.2)2 (13.3)13 (59.1) E-stim11 (25.6)8 ( 7.5)1 ( 2.3)4 (26.7)4 (18.2) EMG18 (41.9)38 (35.5)23 (53.5)9 (60.0)11 (50.0) Ultrasound3 ( 7.0)8 ( 7.5)0 ( 0.0)2 (13.3)1 ( 4.5)[^5][^6][^7]

Clenched fist was most often treated in stroke (70.6% of patients), followed by TBI (55.6%), SCI (40.5%), CP (29.9%), and MS (12.6%; [Table 2](#tbl2){ref-type="table"}). A mean dose of 98 U (CP) to 127 U (TBI) of onabotulinumtoxinA per treatment session was observed, with the most common dose (mode) being 100 U in all etiologies except MS (50 U). Of the injection guidance techniques available, electromyography (EMG) was most often utilized by clinicians to locate the site(s) for injection in CP (62.1% of treatment sessions), stroke (54.9%), SCI (47.9%), and TBI (46.0%). However, anatomical localization was utilized most often in MS (74.4%).

Flexed elbow was most often treated in stroke (67.4% of patients), followed by TBI (57.8%), CP (37.7%), SCI (28.6%), and MS (12.6%; [Table 2](#tbl2){ref-type="table"}). A mean dose of 101 U (CP) to 163 U (MS) of onabotulinumtoxinA per treatment session was observed, with the most common dose being 100 U in all etiologies. EMG was most often utilized by clinicians to locate the site(s) for injection in CP (63.4% of treatment sessions), stroke (56.3%), SCI (52.6%), and TBI (52.4%), while anatomical localization was utilized most often in MS (61.9%).

Flexed wrist was most often treated in stroke (53.8% of patients), followed by CP (37.7%), TBI (28.9%), SCI (19.0%), and MS (6.7%; [Table 2](#tbl2){ref-type="table"}). A mean dose of 54 U (MS) to 97 U (SCI) of onabotulinumtoxinA per treatment session was observed, with the most common dose being 100 U (stroke, TBI, and SCI). EMG was most often utilized by clinicians to locate the site(s) for injection in TBI (63.6% of treatment sessions), stroke (59.5%), and CP (50.0%). However, anatomical localization was most often utilized in MS (88.9%) and anatomical localization and EMG were equally utilized in SCI (56.3% for both methods).

Equinovarus foot was most often treated in TBI (62.2% of patients), followed by MS (60.5%), stroke (52.8%), CP (49.4%), and SCI (47.6%; [Table 3](#tbl3){ref-type="table"}). A mean dose of 162 U (CP) to 277 U (SCI) of onabotulinumtoxinA per treatment session was observed, with the most common dose being 300 U (stroke and MS). EMG was most often utilized by clinicians to locate the site(s) for injection in CP (52.0% of treatment sessions) and stroke (49.9%), while both EMG and anatomical were equally utilized in MS (54.1% for both methods). Anatomical localization was utilized most often in SCI (43.1%) and electrical-stimulation (E-stim) in TBI (64.6%).

Flexed knee was most often treated in CP (33.8% of patients), followed by MS (26.9%), TBI (26.7%), SCI (21.4%), and stroke (9.5%; [Table 3](#tbl3){ref-type="table"}). A mean dose of 143 U (stroke) to 181 U (MS) of onabotulinumtoxinA per treatment session was observed, with the most common dose being 100 U (stroke and CP) or 150 U (MS and TBI). EMG was most often utilized by clinicians to locate the site(s) for injection in CP (74.2% of treatment sessions), SCI (62.5%), stroke (61.3%), and TBI (52.9%). However, anatomical localization was utilized most often in MS (67.7%).

Adducted thigh was most often treated in CP (22.1% of patients), followed by SCI (21.4%), TBI (15.6%), MS (9.2%), and stroke (4.9%; [Table 3](#tbl3){ref-type="table"}). A mean dose of 112 U (stroke) to 173 U (MS) of onabotulinumtoxinA per treatment session was observed, with the most common dose being 100 U (stroke, CP, and SCI). EMG was most often utilized by clinicians to locate the site(s) for injection in TBI (60.0% of treatment sessions), CP (53.5%), and stroke (41.9%), while anatomical localization was utilized most often in MS (72.0%) and SCI (59.1%).

The total body (ie, upper limb and/or lower limb) mean cumulative dose of onabotulinumtoxinA per treatment session ranged from 53 to 1038 U ([Table 4](#tbl4){ref-type="table"}). The mean cumulative dose in each etiology was as follows: 406 U in TBI, 371 U in stroke, 344 U in MS, 343 in SCI, and 296 U in CP. The most common (mode) cumulative dose of onabotulinumtoxinA utilized by clinicians was 300 U (MS, TBI, and SCI).Table 4Mean cumulative dose of onabotulinumtoxinA per treatment session.Table 4Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)Dose (U) Mean (SD)371 (186)344 (177)296 (145)406 (152)343 (186) Mode200300400300300 Min, Max53, 103859, 85060, 620175, 927100, 900[^8]

3.3. Effectiveness {#sec3.3}
------------------

### 3.3.1. Disability Assessment Scale (DAS) {#sec3.3.1}

To evaluate functional impairment resulting from spasticity, DAS scores were collected by the treating clinician. Compared to treatment session 1, DAS scores improved significantly in stroke patients at subsequent treatments for nearly all subscales following treatment with onabotulinumtoxinA, indicative of decreased functional impairment/improved global functional over time, in both the upper limb (all comparisons, *P* \< 0.0001; [Table 5](#tbl5){ref-type="table"}) and the lower limb (all comparisons, *P* \< 0.05 except for hygiene; [Table 6](#tbl6){ref-type="table"}). In CP patients, DAS scores improved over time for the subscale of pain in the upper limb (*P* \< 0.05; [Table 5](#tbl5){ref-type="table"}) and for the subscales of dressing, limb posture, and mobility in the lower limb following onabotulinumtoxinA treatment (*P* \< 0.05; [Table 6](#tbl6){ref-type="table"}). In MS, TBI, and SCI patients, DAS scores improved over time for the subscale of mobility in the lower limb following treatment with onabotulinumtoxinA (*P* \< 0.05; [Table 6](#tbl6){ref-type="table"}); however, no other significant changes were observed. Complete DAS data (treatment sessions 1--4) for each etiology are provided in [Supplemental Tables 3--7](#appsec2){ref-type="fn"}.Table 5Disability Assessment Scale (DAS) for the upper limb.[a](#tbl5fna){ref-type="table-fn"}Table 5Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)Tx1 (N=410)[c](#tbl5fnc){ref-type="table-fn"}Tx4 (N=152)Tx1 (N=116)Tx4 (N=47)Tx1 (N=77)Tx4 (N=28)Tx1 (N=45)Tx4 (N=15)Tx1 (N=42)Tx4 (N=15)Dressing, N (%) 0 - No disability62 (15.1)27 (17.8)76 (65.5)27 (57.4)34 (44.2)9 (32.1)15 (33.3)6 (40.0)21 (50)5 (33.3) 1 - Mild disability100 (24.4)63 (41.4)16 (13.8)4 ( 8.5)16 (20.8)6 (21.4)8 (17.8)4 (26.7)9 (21.4)5 (33.3) 2 - Moderate disability169 (41.2)50 (32.9)10 ( 8.6)8 (17.0)19 (24.7)10 (35.7)16 (35.6)4 (26.7)7 (16.7)3 (20.0) 3 - Severe disability79 (19.3)12 ( 7.9)14 (12.1)8 (17.0)8 (10.4)3 (10.7)6 (13.3)1 ( 6.7)5 (11.9)2 (13.3) Odds ratio3.81.22.22.50.5 95% CI2.4, 6.00.4, 3.90.7, 7.30.6, 11.40.1, 2.4 F-value[b](#tbl5fnb){ref-type="table-fn"}15.90.61.50.81.1 P-value\< 0.00010.6060.2270.4930.910Hygiene, N (%) 0 - No disability105 (25.6)53 (34.9)81 (69.8)29 (61.7)38 (49.4)11 (39.3)16 (35.6)6 (40.0)21 (50.0)5 (33.3) 1 - Mild disability106 (25.9)42 (27.6)10 ( 8.6)6 (12.8)17 (22.1)6 (21.4)14 (31.1)6 (40.0)10 (23.8)6 (40.0) 2 - Moderate disability120 (29.3)41 (27.0)12 (10.3)5 (10.6)13 (16.9)7 (25.0)8 (17.8)2 (13.3)5 (11.9)2 (13.3) 3 - Severe disability79 (19.3)16 (10.5)13 (11.2)7 (14.9)9 (11.7)4 (14.3)7 (15.6)1 ( 6.7)6 (14.3)2 (13.3) Odds ratio2.33.01.42.90.6 95% CI1.5, 3.60.8, 10.70.4, 4.30.7, 12.90.1, 2.7 F-value9.61.61.81.02.7 P-value\< 0.00010.1980.1580.3960.051Limb Posture, N (%) 0 - No disability60 (14.6)21 (13.8)80 (69.0)27 (57.4)35 (45.5)7 (25.0)11 (24.4)4 (26.7)19 (45.2)4 (26.7) 1 - Mild disability62 (15.1)49 (32.2)11 ( 9.5)5 (10.6)8 (10.4)8 (28.6)6 (13.3)2 (13.3)6 (14.3)3 (20.0) 2 - Moderate disability173 (42.2)59 (38.8)13 (11.2)7 (14.9)24 (31.2)9 (32.1)18 (40.0)8 (53.3)10 (23.8)5 (33.3) 3 - Severe disability115 (28.0)23 (15.1)12 (10.3)8 (17.0)10 (13.0)4 (14.3)10 (22.2)1 ( 6.7)7 (16.7)3 (20.0) Odds ratio3.22.11.32.30.7 95% CI2.1, 5.00.6, 7.00.4, 4.00.6, 9.30.1, 3.2 F-value19.21.91.41.00.4 P-value\< 0.00010.1370.2400.4030.729Pain, N (%) 0 - No disability146 (35.6)76 (50.0)89 (76.7)33 (70.2)48 (62.3)14 (50.0)23 (51.1)8 (53.3)21 (50.0)8 (53.3) 1 - Mild disability108 (26.3)46 (30.3)14 (12.1)5 (10.6)19 (24.7)8 (28.6)12 (26.7)6 (40.0)9 (21.4)4 (26.7) 2 - Moderate disability97 (23.7)23 (15.1)7 ( 6.0)4 ( 8.5)9 (11.7)5 (17.9)7 (15.6)1 ( 6.7)10 (23.8)0 ( 0.0) 3 - Severe disability59 (14.4)7 ( 4.6)6 ( 5.2)5 (10.6)1 ( 1.3)1 ( 3.6)3 ( 6.7)0 ( 0.0)2 ( 4.8)3 (20.0) Odds ratio3.61.51.01.71.1 95% CI2.3, 5.80.4, 5.40.3, 3.00.4, 6.90.3, 4.4 F-value19.50.22.71.32.5 P-value\< 0.00010.9120.0480.2710.064[^9][^10][^11][^12]Table 6Disability Assessment Scale (DAS) for the lower limb.[a](#tbl6fna){ref-type="table-fn"}Table 6Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)Tx1 (N=409)[c](#tbl6fnc){ref-type="table-fn"}Tx4 (N=150)Tx1 (N=117)Tx4 (N=54)Tx1 (N=77)Tx4 (N=31)Tx1 (N=45)Tx4 (N=14)Tx1 (N=42)Tx4 (N=15)Dressing, N (%) 0 - No disability131 (32.0)40 (26.7)14 (12.0)11 (20.4)18 (23.4)10 (32.3)15 (33.3)7 (50.0)11 (26.2)5 (33.3) 1 - Mild disability126 (30.8)63 (42.0)36 (30.8)12 (22.2)21 (27.3)13 (41.9)12 (26.7)6 (42.9)11 (26.2)5 (33.3) 2 - Moderate disability116 (28.4)39 (26.0)32 (27.4)19 (35.2)25 (32.5)6 (19.4)12 (26.7)1 ( 7.1)15 (35.7)3 (20.0) 3 - Severe disability36 ( 8.8)8 ( 5.3)35 (29.9)12 (22.2)13 (16.9)2 ( 6.5)6 (13.3)0 ( 0.0)5 (11.9)2 (13.3) Odds ratio1.61.93.52.52.2 95% CI1.0, 2.50.8, 4.51.3, 9.80.6, 11.00.5, 9.5 F-value[b](#tbl6fnb){ref-type="table-fn"}2.81.43.10.60.6 P-value0.0410.2520.0290.6490.594Hygiene, N (%) 0 - No disability196 (47.9)70 (46.7)28 (23.9)17 (31.5)27 (35.1)18 (58.1)22 (48.9)8 (57.1)18 (42.9)6 (40.0) 1 - Mild disability98 (24.0)40 (26.7)25 (21.4)8 (14.8)24 (31.2)7 (22.6)9 (20.0)3 (21.4)11 (26.2)5 (33.3) 2 - Moderate disability82 (20.0)33 (22.0)35 (29.9)17 (31.5)18 (23.4)4 (12.9)9 (20.0)3 (21.4)7 (16.7)3 (20.0) 3 - Severe disability33 ( 8.1)7 ( 4.7)29 (24.8)12 (22.2)8 (10.4)2 ( 6.5)5 (11.1)0 ( 0.0)6 (14.3)1 ( 6.7) Odds ratio1.21.54.41.21.1 95% CI0.8, 2.00.7, 3.61.5, 13.20.2, 6.60.3, 5.2 F-value2.00.42.61.50.5 P-value0.1080.7360.0560.2180.709Limb Posture, N (%) 0 - No disability109 (26.7)41 (27.3)15 (12.8)9 (16.7)14 (18.2)7 (22.6)9 (20.0)5 (35.7)10 (23.8)4 (26.7) 1 - Mild disability104 (25.4)56 (37.3)22 (18.8)13 (24.1)15 (19.5)13 (41.9)11 (24.4)3 (21.4)10 (23.8)4 (26.7) 2 - Moderate disability148 (36.2)42 (28.0)43 (36.8)17 (31.5)33 (42.9)8 (25.8)16 (35.6)5 (35.7)13 (31.0)5 (33.3) 3 - Severe disability48 (11.7)11 ( 7.3)37 (31.6)15 (27.8)15 (19.5)3 ( 9.7)9 (20.0)1 ( 7.1)9 (21.4)2 (13.3) Odds ratio2.62.23.01.52.3 95% CI1.6, 4.01.0, 5.01.2, 7.90.4, 6.20.5, 9.5 F-value7.62.14.00.62.0 P-value\< 0.00010.0990.0090.6140.129Pain, N (%) 0 - No disability201 (49.1)83 (55.3)37 (31.6)14 (25.9)32 (41.6)14 (45.2)22 (48.9)8 (57.1)17 (40.5)6 (40.0) 1 - Mild disability103 (25.2)40 (26.7)23 (19.7)18 (33.3)21 (27.3)7 (22.6)10 (22.2)6 (42.9)7 (16.7)5 (33.3) 2 - Moderate disability74 (18.1)23 (15.3)31 (26.5)13 (24.1)13 (16.9)8 (25.8)9 (20.0)0 ( 0.0)10 (23.8)1 ( 6.7) 3 - Severe disability31 ( 7.6)4 ( 2.7)26 (22.2)9 (16.7)11 (14.3)2 ( 6.5)4 ( 8.9)0 ( 0.0)8 (19.0)3 (20.0) Odds ratio1.92.01.92.51.6 95% CI1.2, 3.10.9, 4.20.7, 5.20.5, 12.40.3, 7.6 F-value10.71.51.90.50.4 P-value\< 0.00010.2050.1270.6630.755Mobility, N (%) 0 - No disability90 (22.0)25 (16.7)4 ( 3.4)4 ( 7.4)10 (13.0)4 (12.9)6 (13.3)4 (28.6)8 (19.0)4 (26.7) 1 - Mild disability73 (17.8)43 (28.7)10 ( 8.5)9 (16.7)11 (14.3)12 (38.7)6 (13.3)3 (21.4)3 ( 7.1)4 (26.7) 2 - Moderate disability165 (40.3)63 (42.0)42 (35.9)20 (37.0)28 (36.4)10 (32.3)21 (46.7)7 (50.0)14 (33.3)5 (33.3) 3 - Severe disability81 (19.8)19 (12.7)61 (52.1)21 (38.9)28 (36.4)5 (16.1)12 (26.7)0 ( 0.0)17 (40.5)2 (13.3) Odds ratio2.14.35.27.28.0 95% CI1.3, 3.31.7, 11.31.9, 14.81.5, 34.31.8, 34.6 F-value4.44.14.92.83.8 P-value0.0040.0070.0030.0490.013[^13][^14][^15][^16]

### 3.3.2. Clinician and patient satisfaction {#sec3.3.2}

In ASPIRE, clinicians and patients were asked a series of questions to determine their satisfaction with onabotulinumtoxinA treatment for spasticity ([Fig. 3](#fig3){ref-type="fig"}). Clinicians reported extreme satisfaction/satisfaction that onabotulinumtoxinA helped their patient\'s spasticity (range: 87.4% \[SCI\] to 94.2% \[CP\] of treatment sessions; [Fig. 3](#fig3){ref-type="fig"}A). Likewise, patients reported extreme satisfaction/satisfaction that onabotulinumtoxinA helped their spasticity (range: 67.6% \[TBI\] to 89.7% \[SCI\]; [Fig. 3](#fig3){ref-type="fig"}B). In addition, clinicians reported extreme satisfaction/satisfaction that onabotulinumtoxinA helped manage their patient\'s spasticity-related pain, if present (range: 82.7% \[TBI\] to 93.5% \[CP\]; [Fig. 3](#fig3){ref-type="fig"}C), with patients showing high agreement with this statement (range: 82.6% \[stroke and TBI\] to 87.0% \[SCI\]; [Fig. 3](#fig3){ref-type="fig"}D). Furthermore, clinicians reported extreme satisfaction/satisfaction that onabotulinumtoxinA helped their patients participate in therapy/exercise (range: 85.2% \[MS\] to 95.5% \[CP\]; [Fig. 3](#fig3){ref-type="fig"}E), with patients showing high agreement with this statement as well (range: 74.2% \[TBI\] to 81.5% \[SCI\]; [Fig. 3](#fig3){ref-type="fig"}F). Lastly, the majority of clinicians (range: 94.6% \[TBI\] to 98.8% \[CP\]; [Fig. 3](#fig3){ref-type="fig"}G) and patients (range: 88.4% \[stroke\] to 91.2% \[TBI\]; [Fig. 3](#fig3){ref-type="fig"}H) responded that they would definitely/probably continue to use onabotulinumtoxinA to manage spasticity.Fig. 3Clinician- and patient-reported satisfaction with onabotulinumtoxinA treatment for spasticity. Clinicians (at each subsequent treatment session; A, C, E, G) and patients (5±1 weeks post-treatment; B, D, F, H) were asked a series of questions to determine their satisfaction with the previous onabotulinumtoxinA (referred to as BOTOX in the original questionnaire) treatment for spasticity. For figures C--F, the percentage of clinicians and patients were recalculated to exclude those that indicated that the question was "not applicable". CP: cerebral palsy, MS: multiple sclerosis, n: number of treatment sessions, TBI: traumatic brain injury, Tx: treatment session, SCI: spinal cord injury.Fig. 3

3.4. Safety {#sec3.4}
-----------

At the 1-year interim, AE and serious AE data varied by etiology of spasticity and are provided in [Supplemental Table 8](#appsec2){ref-type="fn"}. In addition, the total number of treatment-related AEs varied across etiologies (stroke: 10 events \[2.2% of patients\]; MS: 5 events \[4.2%\], CP: 0 events \[0.0%\]; TBI: 1 event \[2.2%\]; SCI: 0 events \[0.0%\]), with muscular weakness being the most common treatment-related AE reported ([Table 7](#tbl7){ref-type="table"}). Few treatment-related serious AEs were reported ([Table 7](#tbl7){ref-type="table"}) and included one case each of dysphagia, muscular weakness, and slow speech in 2 male patients from the stroke population. Neither case was considered related to the distant spread of toxin as adjudicated by a panel of safety clinicians.Table 7Treatment-related adverse events and treatment-related serious adverse events[a](#tbl7fna){ref-type="table-fn"}Table 7Stroke (N=411)MS (N=119)CP (N=77)TBI (N=45)SCI (N=42)Patients,\
N (%)Events, nPatients,\
N (%)Events, nPatients,\
N (%)Events, nPatients,\
N (%)Events, nPatients,\
N (%)Events, nAll TRAEs[b](#tbl7fnb){ref-type="table-fn"} Muscular weakness4 (1.0)43 (2.5)3------------ Dysphagia2 (0.5)2---------------- Asthenia1 (0.2)1---------------- Drug tolerance1 (0.2)1---------------- Dry mouth----1 (0.8)1------------ Grip strength decreased------------1 (2.2)1---- Influenza-like illness----1 (0.8)1------------ Peripheral edema1 (0.2)1---------------- Slow speech1 (0.2)1----------------All TRSAEs[b](#tbl7fnb){ref-type="table-fn"} Dysphagia1 (0.2)1---------------- Muscular weakness1 (0.2)1---------------- Slow speech1 (0.2)1----------------[^17][^18][^19]

4. Discussion {#sec4}
=============

The majority of published data describing the use of onabotulinumtoxinA to treat spasticity are from controlled trials in post-stroke patients (eg, [@bib8], [@bib25], [@bib26], [@bib36], [@bib48]). Real-world, observational data examining onabotulinumtoxinA utilization across other etiologies of spasticity, in addition to stroke, are needed to improve clinical approaches and optimize patient care. The aims for this 1-year interim analysis of the ASPIRE study were to describe the real-world patterns of onabotulinumtoxinA utilization across several etiologies of spasticity and evaluate the effectiveness of onabotulinumtoxinA to treat spasticity across these etiologies via clinician- and patient-reported outcomes.

OnabotulinumtoxinA utilization data from ASPIRE revealed similarities and differences in clinical approaches to treat spasticity across five common etiologies -- stroke, MS, CP, TBI, and SCI. OnabotulinumtoxinA utilization data from ASPIRE are highly generalizable and reflect the complexity of treating patients in the real-world. In clinical practice, dosing decisions can be impacted by country-specific dosing regulations, treatment history, severity of spasticity, number and location of muscles targeted, and experience of the treating clinician, amongst others ([@bib10], [@bib18], [@bib41], [@bib42]).

In this 1-year analysis of ASPIRE, clenched fist was the most commonly treated upper limb presentation in stroke, MS, and SCI, while flexed wrist and flexed elbow were most commonly treated in CP and TBI, respectively. Within the lower limb, equinovarus foot was the most commonly treated presentation in all etiologies. The dose ranges of onabotulinumtoxinA utilized by clinicians showed consistency within the upper limb versus the lower limb. Specifically, across the three most common upper limb presentations (clenched fist, flexed elbow, and flexed wrist), dose ranges were highest when treating post-stroke patients. In contrast, across the three most common lower limb presentations (equinovarus foot, flexed knee, and adducted thigh), dose ranges were highest when treating patients with MS. There are several possible explanations for the observed variability in dosing between etiologies. For example, differences in spasticity presentation (eg, higher weakness associated with a specific etiology), location and size of muscles targeted (eg, MS patients were often treated for lower limb spasticity in ASPIRE, with larger muscles generally found in the lower limb), or severity of spasticity (eg, a specific etiology may typically present with greater severity) could all affect the dose of onabotulinumtoxinA utilized by clinicians.

Furthermore, onabotulinumtoxinA dosing for the most common clinical presentations in the upper limb were generally lower and less variable between etiologies compared to the lower limb. For example, the most common dose (mode) of onabotulinumtoxinA utilized, which was similar to the mean dose, was 100 U to treat clenched fist (4 out of 5 etiologies), flexed elbow (all etiologies), and flexed wrist (3 out of 5 etiologies). In contrast, common dosing patterns were less apparent for the lower limb presentations of equinovarus foot, flexed knee, and adducted thigh. For example, the most common dose of onabotulinumtoxinA utilized for equinovarus foot varied by etiology, with 300 U utilized in stroke and MS, 200 U in SCI, 150 U in TBI, and 100 in CP. Despite the variability in doses of onabotulinumtoxinA utilized by clinicians, the total body (ie, upper and/or lower limb) mean cumulative dose of onabotulinumtoxinA per treatment session (range: 296 U \[CP\] to 406 U \[TBI\]) was near or below that recommended on the product label (400 U; [@bib2]). Combined, these dosing data from ASPIRE demonstrate the individualized approach used by clinicians when treating patients with onabotulinumtoxinA from various etiologies of spasticity. Indeed, an individualized and flexible approach to botulinum toxin therapy has been discussed in the literature, as a single approach is unlikely to suit all patients or disease states ([@bib49]).

Injection localization methods, such as EMG, E-stim, and ultrasound, have been recommended to improve the localization of target muscles for injection ([@bib38], [@bib37][@bib37][@bib38], [@bib41], [@bib45]). A review by [@bib11] found level I evidence that using injection localization methods improved patient outcomes (eg, MMAS, range of motion, limb placement, and Tardieu Scale) compared to manual needle placement alone. In ASPIRE, EMG was utilized by clinicians in approximately half of all treatment sessions for the majority of presentations in both the upper and lower limb in stroke, CP, TBI, and SCI. In contrast, clinicians treating MS showed a preference for anatomical localization compared to instrumented guidance techniques. As these are real-world data, they reflect the injection techniques used by treating clinicians in actual practice, which may be indicative of their preferences, but also may have been influenced by the equipment that was available at the study sites. Finally, these data suggest that there may be an educational opportunity to inform clinicians of the benefits of guided localization methods to improve patient outcomes with botulinum toxin therapy.

To assess the effectiveness of onabotulinumtoxinA to treat upper and/or lower limb spasticity, PRO data were collected throughout the course of the study from all etiologies. Functional impairment was assessed by the clinician at each treatment session using DAS ([@bib9]) and clinician- and patient-reported satisfaction data were gathered following each onabotulinumtoxinA treatment. At the 1-year interim analysis, among stroke patients, DAS scores were significantly reduced in the upper and lower limbs across the subscales of dressing, hygiene (excluding lower limb), limb posture, pain, and mobility, demonstrating improved global function and quality of life following repeated onabotulinumtoxinA treatment. Additionally, among MS, CP, TBI, and SCI patients, DAS scores significantly improved in the lower limb for the subscale of mobility following onabotulinumtoxinA treatment. These changes in DAS are a meaningful finding for patients, as increased disability on the DAS has been associated with reductions in health-related quality of life in post-stroke spasticity patients ([@bib15]). Improvements in DAS are likely a reflection of goal selection (ie, active vs. passive) and influenced by clinical presentations that are common to specific etiologies, time to treatment after onset of spasticity, and many other factors.

Across all etiologies, the majority of patients and clinicians reported that they were satisfied with onabotulinumtoxinA treatment and would continue to use onabotulinumtoxinA to treat spasticity. Patients and clinicians in ASPIRE reported that onabotulinumtoxinA treatment helped reduce their/their patient\'s spasticity-related pain and helped them/their patients participate in therapy/exercise. Spasticity-related pain has been associated with reduced quality of life ([@bib4], [@bib22]), as well as economic losses due to decreased work productivity ([@bib28]). Importantly, adjunct therapies have been shown to improve patient outcomes, including a reduction in hypertonicity and improvements on the Modified Ashworth Scale over time, following treatment with botulinum toxins ([@bib21], [@bib32], [@bib40]). Interestingly, patients with TBI consistently reported the lowest satisfaction with onabotulinumtoxinA treatment and its ability to help them participate in therapy/exercise or help their spasticity-related pain, yet these patients reported that they were the most willing to continue onabotulinumtoxinA treatment compared to all other etiologies. The findings of decreased satisfaction in patients with TBI may be due, in part, to the higher complexity of spasticity patterns often observed in this patient population. Treating TBI patients may require different clinical approaches (eg, more frequent dosing) and/or higher mean doses of onabotulinumtoxinA, which may be restricted by country-specific dosing regulations and/or insurance coverage.

Data from this 1-year interim analysis of ASPIRE support the safety of onabotulinumtoxinA to treat adult spasticity across several etiologies, including stroke, MS, CP, TBI, and SCI. OnabotulinumtoxinA demonstrated an acceptable safety profile, with no new safety signals identified. Adverse event data captured in this analysis of ASPIRE are consistent with safety data within the literature and global labelling ([@bib2], [@bib8], [@bib13], [@bib26]).

Limitations of the ASPIRE study have been discussed previously ([@bib20]). Of relevance to this interim analysis, the number of patients within each etiology was not preordained and varied according to patient recruitment at the study sites, resulting in uneven sample sizes amongst etiologies. Due to this variability, results in post-stroke patients are likely more robust due to the larger sample size (N=411) compared to the other etiologies (eg, TBI \[N=45\] or SCI \[N=42\]). In addition, the number of treatments received in a 1-year period varies among patients due to several factors, such as a patient\'s severity of spasticity, experience of clinician, previous response to treatment (ie, duration of effect), and other factors. Therefore, data from later treatment sessions (within the 1-year interim) should be interpreted with caution due to lower sample sizes. Future analyses from ASPIRE will need to determine the impact of etiology of spasticity on other factors, such as treatment adherence, as well as describe the patterns of onabotulinumtoxinA utilization and clinician- and patient-reported outcomes for the completed 2-year study.

5. Conclusions {#sec5}
==============

High clinician- and patient-reported satisfaction were observed across all etiologies of spasticity following individualized onabotulinumtoxinA treatment in ASPIRE, as well as improved global function based on DAS. These real-world data highlight the similarities and differences in treating patients across several common etiologies, providing an important educational tool to help guide clinical strategies on the use of onabotulinumtoxinA to treat spasticity.
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[^1]: BMI: body mass index, CP: cerebral palsy, Max: maximum, Min: minimum, MS: multiple sclerosis, N: number of patients, SD: standard deviation, TBI: traumatic brain injury, SCI: spinal cord injury.

[^2]: CP: cerebral palsy, E-stim: electrical stimulation, EMG: electromyography, Max: maximum, mL: milliliter, Min: minimum, MS: multiple sclerosis, N: number of patients, n: number of treatment sessions, SCI: spinal cord injury, SD: standard deviation, TBI: traumatic brain injury, U: units of onabotulinumtoxinA.

[^3]: For each etiology, the upper limb spasticity presentations were first ranked by number of patients treated: highest to lowest. Next, the number of times each spasticity presentation was included in the top 3 ranking was counted and the 3 presentations with the highest number of top 3 rankings are shown here. Upper limb spasticity presentations are not mutually exclusive, and therefore, may add up to greater than 100%.

[^4]: Localization methods were not mutually exclusive and may have been influenced by availability of equipment at the site. "Anatomical" localization refers to palpation. Data represents the sum across all treatment sessions in the 1-year interim analysis.

[^5]: CP: cerebral palsy, E-stim: electrical stimulation, EMG: electromyography, Max: maximum, mL: milliliter, Min: minimum, MS: multiple sclerosis, N: number of patients, n: number of treatment sessions, SCI: spinal cord injury, SD: standard deviation, TBI: traumatic brain injury, U: units of onabotulinumtoxinA.

[^6]: For each etiology, the lower limb spasticity presentations were first ranked by number of patients treated: highest to lowest. Next, the number of times each spasticity presentation was included in the top 3 ranking was counted and the 3 presentations with the highest number of top 3 rankings are shown here. Lower limb spasticity presentations are not mutually exclusive, and therefore, may add up to greater than 100%.

[^7]: Localization methods were not mutually exclusive and may have been influenced by availability of equipment at the site. "Anatomical" localization refers to palpation. Data represents the sum across all treatment sessions in the 1-year interim analysis.

[^8]: CP: cerebral palsy, Max: maximum, Min: minimum, MS: multiple sclerosis, N: number of patients, SCI: spinal cord injury, SD: standard deviation, TBI: traumatic brain injury, U: units of onabotulinumtoxinA.

[^9]: CI: confidence interval, CP: cerebral palsy, MS: multiple sclerosis, N: number of patients, SCI: spinal cord injury, TBI: traumatic brain injury, Tx: treatment session.

[^10]: DAS objectively evaluates functional impairment resulting from spasticity across several subscales, including dressing, hygiene, limb posture, and pain ([@bib9]). Patients were scored on a 4-point scale (range: 0--3) for each subscale, where a "0" represents no disability and a "3" represents severe disability (normal activities limited). DAS was assessed by the clinician at treatment session 1 and at each subsequent treatment session. However, to allow for comparison across etiologies, only treatment sessions 1 and 4 are shown here. Complete DAS data tables are provided in the supplemental materials for each etiology.

[^11]: Data were analyzed using ordinal logistic regression. The F-value and level of significance (P-value) are shown for each subscale for the comparison across treatment sessions 1 to 4.

[^12]: Data from treatment session 1 for each etiology were used as the reference for statistical analysis.

[^13]: CI: confidence interval, CP: cerebral palsy, MS: multiple sclerosis, N: number of patients, SCI: spinal cord injury, TBI: traumatic brain injury, Tx: treatment session.

[^14]: DAS objectively evaluates functional impairment resulting from spasticity across several subscales, including dressing, hygiene, limb posture, and pain ([@bib9]). Patients were scored on a 4-point scale (range: 0--3) for each subscale, where a "0" represents no disability and a "3" represents severe disability (normal activities limited). DAS was assessed by the clinician at treatment session 1 and at each subsequent treatment session. However, to allow for comparison across etiologies, only treatment sessions 1 and 4 are shown here. Complete DAS data tables are provided in the supplemental materials for each etiology.

[^15]: Data were analyzed using ordinal logistic regression. The F-value and level of significance (P-value) are shown for each subscale for the comparison across treatment sessions 1 to 4.

[^16]: Data from treatment session 1 for each etiology were used as the reference for statistical analysis.

[^17]: CP: cerebral palsy, MS: multiple sclerosis, n: number of adverse events, N: number of patients, SCI: spinal cord injury, TBI: traumatic brain injury, TRAE: treatment-related adverse events, TRSAE: treatment-related serious adverse events.

[^18]: All TRAE and TRSAE data are shown.

[^19]: For each TRAE and TRSAE, the number of patients that reported the event were totaled across all etiologies and arranged in descending order.
